Back

Studying a human genetic model of lung squamous cell carcinoma with organotypic cultures and xenografts uncovers distinct advantages of each system and implicates NOTCH1 loss in tumour development

Ogden, J.; Sellers, R.; Oojageer, A.; Sahoo, S.; Dive, C.; Lopez-Garcia, C.

2025-09-01 cancer biology
10.1101/2025.08.28.672595 bioRxiv
Show abstract

Selecting appropriate experimental systems is crucial in cancer research, where factors such as model relevance, cost, and resource availability guide decisions. A detailed understanding of the strengths and limitations of each model helps ensure their optimal use. We recently developed a human lung squamous cell carcinoma (LUSC) model using genetically engineered human bronchial epithelial cells (hBECs). These were studied through organotypic air-liquid interface (ALI) cultures and standard in vitro assays, including proliferation, invasion, and anchorage-independent growth. However, we did not evaluate whether the same mutant hBECs behaved similarly in vivo, or if in vivo models offered distinct advantages. To address this, we conducted a comparative phenotypic analysis of mutant hBECs derived from the same donor in both ALI cultures and xenografts in immunocompromised mice. Both models followed a similar oncogenic trajectory, involving squamous differentiation and activation of Nrf2 and PI3K/Akt pathways, characteristic of the classical LUSC subtype. However, some transcriptomic differences related to an increase in microtubule formation and cell motility in xenografts emerged. Additionally, xenograft gene expression profiles more closely matched classical LUSC tumours than ALI cultures. Importantly, we observed spontaneous squamous differentiation in the absence of SOX2 overexpression and detected selection for NOTCH1 mutations in specific in vivo mutants. Truncation of NOTCH1 promoted squamous differentiation and suppressed mucociliary features in ALI cultures, underscoring its role as a potential LUSC driver. In summary, mutant hBECs in vitro and in vivo showed largely consistent phenotypes, validating both systems. However, in vivo models can enable the unbiased discovery of new genetic LUSC driver genes. This highlights the complementary value of integrating both model types in LUSC research.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
Cancers
200 papers in training set
Top 0.1%
18.4%
2
Disease Models & Mechanisms
119 papers in training set
Top 0.1%
10.0%
3
Molecular Oncology
50 papers in training set
Top 0.1%
10.0%
4
Scientific Reports
3102 papers in training set
Top 20%
6.3%
5
eLife
5422 papers in training set
Top 20%
4.3%
6
British Journal of Cancer
42 papers in training set
Top 0.5%
2.7%
50% of probability mass above
7
Frontiers in Oncology
95 papers in training set
Top 2%
2.1%
8
Translational Oncology
18 papers in training set
Top 0.1%
2.1%
9
Nature Communications
4913 papers in training set
Top 49%
1.9%
10
PLOS ONE
4510 papers in training set
Top 51%
1.9%
11
Molecular Cancer Research
42 papers in training set
Top 0.2%
1.9%
12
International Journal of Cancer
42 papers in training set
Top 0.7%
1.7%
13
Cancer Research Communications
46 papers in training set
Top 0.6%
1.3%
14
Oncotarget
15 papers in training set
Top 0.2%
1.3%
15
Molecular Cancer
14 papers in training set
Top 0.6%
1.2%
16
Genome Medicine
154 papers in training set
Top 6%
1.2%
17
Experimental Dermatology
10 papers in training set
Top 0.2%
1.1%
18
Cancer Research
116 papers in training set
Top 3%
0.9%
19
Cancer Letters
32 papers in training set
Top 0.5%
0.9%
20
EBioMedicine
39 papers in training set
Top 0.8%
0.9%
21
JCI Insight
241 papers in training set
Top 6%
0.9%
22
EMBO Molecular Medicine
85 papers in training set
Top 3%
0.9%
23
Frontiers in Cell and Developmental Biology
218 papers in training set
Top 8%
0.8%
24
The EMBO Journal
267 papers in training set
Top 5%
0.8%
25
Archives of Toxicology
14 papers in training set
Top 0.3%
0.7%
26
Clinical Cancer Research
58 papers in training set
Top 2%
0.7%
27
Cell Reports
1338 papers in training set
Top 33%
0.7%
28
Life Science Alliance
263 papers in training set
Top 2%
0.7%
29
Cell Genomics
162 papers in training set
Top 7%
0.7%
30
Journal of Cell Science
353 papers in training set
Top 3%
0.7%